Jump to content
World's Largest Herpes Support Group
Sign in to follow this  
wwdamron

Professor Ian Frazer BREAKING NEWS

Recommended Posts

wwdamron

In 2006, clinical immunologist Professor Ian Frazer was named Australian of the Year for developing a vaccine to prevent and treat cervical cancer.

I believe he was also nominated for the Nobel Prize.

This same Professor could outdue Dr. Cullen. He along with Dr Jian Zhou(and his wife), developed the HPV Vaccine and are now working on other vaccines including HSV.

Share this post


Link to post
Share on other sites
officefan

This seems like the article you're referring to: http://www.lifescientist.com.au/article/376895/feature_dna_vaccine_vanguard/

Yes, it does seem like they're further along than Cullen and Bloom--preparing to publish results on animal studies and actually talking about human trials. I wonder if Australia's drug approval process is less complicated and time consuming. Time to start accumulating frequent flier miles on Qantas..

Share this post


Link to post
Share on other sites
smithconfused

Awesome news. But, it looks like that it is a preventative vaccine for people who do not have herpes.

Share this post


Link to post
Share on other sites
officefan

Where do you see that? On Coridon's (Frazer's private company) website it states: "Coridon is currently in the pre-clinical phase of evaluating a combined prophylactic and therapeutic HSV-2 vaccine with a view to commencing a human phase 1b clinical trial in late 2011." So, not just preventative--although if it was only a preventative vaccine that would still be great.

Share this post


Link to post
Share on other sites
accelerate the response

I am more than looking forward to the academic paper supporting this, for if it works and is scheduled for a phase 1b by the end of 2011 then we really are on the way to defeating this evil thing.

aic 316 will block viral reactivation pending this vaccine, which should, if effective, generate a sufficiently strong immune response to ensure that the virus can not break out from latency.

Ultimately, Cellectis will generate a total cure based on meganucleases and their capacity to 'clip' the DNA of the virus within the cell and so totally disenable it. This will not happen for at least ten years or so, and so the potential for this vaccine meanwhile is absolutely enormous. I wish them every success. It's going to a be an Aussie holiday soon for me I think: 'Good On Yer Mate'!

Share this post


Link to post
Share on other sites
Sabrina32

This is great.let's hope it all goes as planned. I sure hope the ausiie approval process isn't like the fda here.

Share this post


Link to post
Share on other sites
Frizzle

wow more great news... anyone know how long till they are in the final phase? or if anything on the market? does it cure those with hsv2?

Share this post


Link to post
Share on other sites
helpiamconfused2
This is great.let's hope it all goes as planned. I sure hope the ausiie approval process isn't like the fda here.

Sabrina, I did a quick look at the Aussie approval process and it APPEARS to take LONGER than the US (hard to believe). Someone needs to double check me on this and if this is the case, I hope they go the US route...

Share this post


Link to post
Share on other sites
wwdamron

THIS IS SIGNIFICANT !!

Thursday February 24, 2011

Professor Ian Frazer earns top job at TRI

The world-renowned co-inventor of the cervical cancer vaccine, Professor Ian Frazer, has been appointed chief executive of the new $345 million Translational Research Institute.

Professor Frazer has been a researcher and academic at The University of Queensland since 1985, and director of The University of Queensland Diamantina Institute since 1997. He was Australian of the Year in 2006 and has won numerous national and international awards.

Alongside his new role, Professor Frazer will continue to lead a large and important UQDI research group.

Professor Matt Brown, an internationally recognised researcher into auto-immune diseases, has been appointed interim director of the UQDI, and will move into the role in April 2011.

When the TRI opens in Brisbane in 2012, it will be the largest institute of its type in the southern hemisphere - and one of only a handful worldwide that can research, trial treatments and manufacture breakthrough drugs in one location.

The TRI will accommodate up to 650 researchers from its four partners: The University of Queensland, Queensland University of Technology, Mater Medical Research Institute and the Princess Alexandra Hospital.

Professor Frazer, whose new role begins in July, said he was honoured to accept the appointment and excited about future discoveries and advances in medical research that would be made at the TRI.

"There are a number of pressing human health issues in the world such as diabetes, cervical and prostate cancer, melanoma and obesity, and I am proud to be leading TRI in researching and developing treatments for these diseases," he said.

"Importantly, patients, the Australian economy and our medical industry will all benefit from TRI's ability to manufacture and commercialise these treatments.

"Too often, Australia loses promising medical scientists to overseas institutions as we are not able currently to support the development of new medical treatments and their translation from research to clinical practice.

"The TRI will change all of this, resulting in the retention of our brightest minds and therefore better health care for all Australians.

"If the TRI and its manufacturing capabilities had been established at the time of the development of the cervical cancer vaccine, much more of the economic benefit from its $5 billion-plus of worldwide sales would have returned to Australia."

Professor Brown paid tribute to Professor Frazer's inspiring leadership at the UQDI and said the Institute's research programs would continue to focus on delivering practical outcomes to patients.

Professor Brown said he was thrilled to have the opportunity to lead the UQDI into new territory.

The move of UQDI into the TRI would further enhance UQDI's ability to fulfil its central mission of turning scientific discoveries into better treatments.

The TRI chairman, Dr David Watson, said Professor Frazer played a large role in the development of the TRI vision and was the best person to move it forward.

"Appointing the right person was crucial, as the CEO will be the key driver of the vision to create an Australian-first home for medical research, clinical trials and treatment commercialisation," Dr Watson said.

"The Board is delighted that Professor Frazer has accepted the position of CEO."

The TRI, at Woolloongabba, will cover five floors and provide 32,000sq m of research space.

Media: Jodi Clyde-Smith, UQDI, +61 7 3176 5938, +61 434 602 949, Fiona Cameron, UQ Communications, ph +61 7 3346 7086

Funding

The TRI's $354 million funding includes the following grants:

- $140 million from the Australian Government

- $107 million from the Queensland Government

- $50 million from The Atlantic Philanthropies

- $25 million from QUT

- $10 million from UQ

- $10 million from the Australian Government for biopharmaceutical manufacturing

Source: The University Of Queensland http://www.uq.edu.au/news/index.html?article=22732

Share this post


Link to post
Share on other sites
wwdamron
this is significant !!

thursday february 24, 2011

professor ian frazer earns top job at tri

the world-renowned co-inventor of the cervical cancer vaccine, professor ian frazer, has been appointed chief executive of the new $345 million translational research institute.

Professor frazer has been a researcher and academic at the university of queensland since 1985, and director of the university of queensland diamantina institute since 1997. He was australian of the year in 2006 and has won numerous national and international awards.

Alongside his new role, professor frazer will continue to lead a large and important uqdi research group.

Professor matt brown, an internationally recognised researcher into auto-immune diseases, has been appointed interim director of the uqdi, and will move into the role in april 2011.

When the tri opens in brisbane in 2012, it will be the largest institute of its type in the southern hemisphere - and one of only a handful worldwide that can research, trial treatments and manufacture breakthrough drugs in one location.

The tri will accommodate up to 650 researchers from its four partners: The university of queensland, queensland university of technology, mater medical research institute and the princess alexandra hospital.

Professor frazer, whose new role begins in july, said he was honoured to accept the appointment and excited about future discoveries and advances in medical research that would be made at the tri.

"there are a number of pressing human health issues in the world such as diabetes, cervical and prostate cancer, melanoma and obesity, and i am proud to be leading tri in researching and developing treatments for these diseases," he said.

"importantly, patients, the australian economy and our medical industry will all benefit from tri's ability to manufacture and commercialise these treatments.

"too often, australia loses promising medical scientists to overseas institutions as we are not able currently to support the development of new medical treatments and their translation from research to clinical practice.

"the tri will change all of this, resulting in the retention of our brightest minds and therefore better health care for all australians.

"if the tri and its manufacturing capabilities had been established at the time of the development of the cervical cancer vaccine, much more of the economic benefit from its $5 billion-plus of worldwide sales would have returned to australia."

professor brown paid tribute to professor frazer's inspiring leadership at the uqdi and said the institute's research programs would continue to focus on delivering practical outcomes to patients.

Professor brown said he was thrilled to have the opportunity to lead the uqdi into new territory.

The move of uqdi into the tri would further enhance uqdi's ability to fulfil its central mission of turning scientific discoveries into better treatments.

The tri chairman, dr david watson, said professor frazer played a large role in the development of the tri vision and was the best person to move it forward.

"appointing the right person was crucial, as the ceo will be the key driver of the vision to create an australian-first home for medical research, clinical trials and treatment commercialisation," dr watson said.

"the board is delighted that professor frazer has accepted the position of ceo."

the tri, at woolloongabba, will cover five floors and provide 32,000sq m of research space.

media: Jodi clyde-smith, uqdi, +61 7 3176 5938, +61 434 602 949, fiona cameron, uq communications, ph +61 7 3346 7086

funding

the tri's $354 million funding includes the following grants:

- $140 million from the australian government

- $107 million from the queensland government

- $50 million from the atlantic philanthropies

- $25 million from qut

- $10 million from uq

- $10 million from the australian government for biopharmaceutical manufacturing

source: The university of queensland http://www.uq.edu.au/news/index.html?article=22732

what makes this so significant is that he's the ceo, which means he's the boss of bosses, he has 650 people who will be at his disposal and he can tell them i want herpes cure research to be a priority, this company can research, develop and put to market any new drug it wants pretty much, and he has almost carte blanc to do it with !!!!!!!!!

I SUGGEST EVERYONE TO CONTACT DR. FRAZER, GET HSV TO BE IN HIS MIND LET IT BECOME HIS PRIORITY, THAN MAYBE WE WILL SEE THE CURE VERY VERY SOON.

Share this post


Link to post
Share on other sites
wmlb87

This is awesome news. A professor with a reputation of excellence, and one who is already making great progress on a Herpes vaccine, just received an abundance of resources to use at his discretion. Hopefully his team can put something together quickly.

Share this post


Link to post
Share on other sites
helpiamconfused2
what makes this so significant is that he's the ceo, which means he's the boss of bosses, he has 650 people who will be at his disposal and he can tell them i want herpes cure research to be a priority, this company can research, develop and put to market any new drug it wants pretty much, and he has almost carte blanc to do it with !!!!!!!!!

I SUGGEST EVERYONE TO CONTACT DR. FRAZER, GET HSV TO BE IN HIS MIND LET IT BECOME HIS PRIORITY, THAN MAYBE WE WILL SEE THE CURE VERY VERY SOON.

His email address is below. I agree. Let's express our support!!!!

Email: di.director@uq.edu.au

My email to him:

Hi from here in the US. May I say we read the news of your HSV 2 research yesterday and there is a LARGE BUZZ here in the States.

We wish you well and please let us know if there is anything we can do to help. There is a large forum of people rooting for you on herpes-coldsores.com.

Warmest regards,

Share this post


Link to post
Share on other sites
helpiamconfused2

email address

uh oh helpiamconfused where did you find that out?

I got the email address by clicking on the name inwwdamrons thread with the article in it above. If it is wrong pls say so, etc... So we can correct it.

Share this post


Link to post
Share on other sites
Sabrina32

No. The email address is fine. I meant where did you find out that the austrailian regulatory process was longer than the united states?

Share this post


Link to post
Share on other sites
Sweet7

Go Aussies!!! This is very exciting news. I'm getting ready to add this to my list. So, does anybody know if they are going to need more money? Maybe we can help. The NIH could grant them funding too.

Share this post


Link to post
Share on other sites
helpiamconfused2
No. The email address is fine. I meant where did you find out that the austrailian regulatory process was longer than the united states?

I Googled their approval process and saw charts comparing the times. It looked like Canada and Australia were both longer than the US. I hope I am wrong. Check it out yourself... Again, I hope I am wrong.

Share this post


Link to post
Share on other sites
camomile

This sounds very real.

Looking far more concrete than any other.

I think this team would well be a candidate for a Nobel Prize (unless it was awarded to him already).

Share this post


Link to post
Share on other sites
camomile
I Googled their approval process and saw charts comparing the times. It looked like Canada and Australia were both longer than the US. I hope I am wrong. Check it out yourself... Again, I hope I am wrong.

I should think this type of vaccine would fall into some special category. (remember how quick vaccine for HPV came on the market?) They are dealing with some "hurdles", which need to be sorted out first.

Share this post


Link to post
Share on other sites
helpiamconfused2
I should think this type of vaccine would fall into some special category. (remember how quick vaccine for HPV came on the market?) They are dealing with some "hurdles", which need to be sorted out first.

Camomile, how long did it take HPV to come to market? Was it fast-tracked??? If so, maybe hope for HSV. The bad thing is that so many things get started (Agenus, Vical, et al) go thru a phase I and stop due to lack of funding. This is where it looks like the US gvt, or some gvt would step in and help.

Share this post


Link to post
Share on other sites
wwdamron

Yes, even though Austrailia may be longer to get vaccines through the market, You are dealing with the former Austrailian Man of the Year, and I'm sure his relationship is quite cozy with some of the leaders in government not to mention Professor Frazer is pretty much going to be the head of research for all of Austrailia, I'm sure he can get things moved through the pipeline much quicker and like I said before he pretty much has a Blank Check to do it with, other than say a Dr. Cullen or Professor Bloom(even though I'm not knocking their research).

Share this post


Link to post
Share on other sites
Sabrina32

hi help I saw the chart you were referring to but then i went the aussie government website and it appears that they have adopted the time frame usually used in europe so Im hoping that its that way instead. Crossing my fingers. :) I sent dr frazer a note saying thanks and to keep up the good work. I really feel that this decade we will get something that helps us.

Share this post


Link to post
Share on other sites
Sabrina32
I am more than looking forward to the academic paper supporting this, for if it works and is scheduled for a phase 1b by the end of 2011 then we really are on the way to defeating this evil thing.

aic 316 will block viral reactivation pending this vaccine, which should, if effective, generate a sufficiently strong immune response to ensure that the virus can not break out from latency.

Ultimately, Cellectis will generate a total cure based on meganucleases and their capacity to 'clip' the DNA of the virus within the cell and so totally disenable it. This will not happen for at least ten years or so, and so the potential for this vaccine meanwhile is absolutely enormous. I wish them every success. It's going to a be an Aussie holiday soon for me I think: 'Good On Yer Mate'!

i agree with everything you said! The potential for this is going to be huge. because guardasil did so well here in the us the fda would be more inclined to approve something that dr frazer has created. I'd love an aussie holiday and if i could kick this evil viruses butt in the process it would triple the fun.

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
Sign in to follow this  

Advertisement

Try a Lysine supplement for cold sores

×